CPT 92202, in plain terms, covers Extended examination of the eye with a detailed drawing of the optic nerve or macula, one or both eyes. CPT 92202 is referenced in 5 tracked payer policy changes from Aetna Better Health of Virginia and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 92202 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 92202 on AAPC
Aetna Better Health of Virginia is correcting an error that caused claims to be wrongly denied when E&M services were billed together with specific ophthalmological procedure codes. The payer has removed these codes from the denial trigger list retroactively to July 1, 2025, and will automatically reprocess all affected claims after system updates are complete by February 1, 2026.
Aetna's Extended Ophthalmoscopy policy (CPB 0767) was reviewed on 2026-10-28 and establishes medical necessity criteria for CPT codes 92201 and 92202. The policy covers extended ophthalmoscopy with detailed retinal drawing for specific clinical indications (such as diabetic retinopathy, retinal detachment, glaucoma, and high myopia) but explicitly excludes cases where routine ophthalmoscopy showed normal findings. The policy also lists indications deemed experimental/investigational (such as monitoring certain medications, neurodegenerative diseases, and retinoblastoma screening) where extended ophthalmoscopy is not covered.
Aetna covers voretigene neparvovec-rzyl (Luxturna) for commercial medical plans, and precertification is required of all Aetna participating providers and members in applicable plan designs. Aetna considers one-time administration per eye medically necessary for biallelic RPE65 mutation-associated retinal dystrophy when the member meets the listed criteria. Repeat administration in the same eye is considered experimental, investigational, or unproven, and the medication must be prescribed by or in consultation with an ophthalmologist.
Aetna Clinical Policy Bulletin 1039 covers transverse venous sinus stent placement for medically refractory idiopathic intracranial hypertension. CPT 61635 and the listed stent HCPCS codes are covered when the policy's selection criteria are met, and intravascular ultrasound (CPT 37252 and 37253) is considered experimental, investigational or unproven for optimizing candidate selection.
Aetna considers extended ophthalmoscopy with a detailed retinal drawing (CPT 92201 and 92202) medically necessary for evaluation of the posterior portion of the eye after routine ophthalmoscopy for listed indications such as retinal detachment, diabetic retinopathy, macular degeneration, uncontrolled glaucoma or glaucoma suspect, and high axial length myopia of -6.00 diopters or less. It is not medically necessary when routine ophthalmoscopy showed normal clinical findings, and a repeat examination is medically necessary only when there is a change in signs, symptoms or condition for an indication that may progress. The service must add information not available from standard evaluation services or information that will demonstrably affect the treatment plan, and it is considered experimental, investigational or unproven for conditions such as optic neuritis, sickle cell disease and screening for retinoblastoma.
Watch 92202
Get one email when a payer policy names 92202, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 92202
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 92202 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.